Chemical Biology | Industry Spotlights & Insight Articles

Targeting Novel E3 Ubiquitin Ligases: Carles Galdeano, Professor, University of Barcelona

We discuss working on PROTACs, targeting novel E3 ubiquitin ligases, and Dr Galdeano's spin out Oniria Therapeutics.

 

Like this interview? See more below:

 

Join and network with over 450 industry discovery biology and chemistry leaders at the renowned Drug Discovery Summit in Basel, where they address critical strategies in target identification, validation
and HIT optimisation of small and large molecule drugs
.